Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | WDR5 | P61964 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6941523 | 1.00 | LMNA (0.47) | LMNAHPGDWDR5HDAC8APEX1 | |
| SCHEMBL6943685 | 0.85 | LMNA (0.45) | LMNAHPGDWDR5APEX1ACACB | |
| SCHEMBL6943689 | 0.85 | LMNA (0.45) | LMNAHPGDWDR5APEX1ACACB | |
| SCHEMBL6944906 | 0.81 | LMNA (0.54) | LMNAHPGDWDR5APEX1SMN1; SMN2 | |
| SCHEMBL7372290 | 0.77 | PPARA (0.53) | GAA | |
| SCHEMBL688476 | 0.77 | GABRP (0.51) | LMNAAPEX1SMN1; SMN2MAPT | |
| SCHEMBL6939383 | 0.77 | GABRP (0.51) | LMNAAPEX1SMN1; SMN2MAPT | |
| SCHEMBL29611681 | 0.77 | GABRP (0.51) | LMNAAPEX1SMN1; SMN2MAPT | |
| SCHEMBL688477 | 0.77 | GABRP (0.51) | LMNAAPEX1SMN1; SMN2MAPT | |
| SCHEMBL6943727 | 0.76 | RORC (0.48) | LMNASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1080069-B1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-03-19 | — | — | EP | disclosed |
| US-6384080-B1 | TREATMENT AND/OR PREVENTION OF CERTAIN CARDIOVASCULAR DISORDERS, UROGENITAL DISORDERS, RESPIRATORY SYSTEM DISORDERS, DISORDERS OF GUT MOTILITY, SEXUAL DISORDERS, DIABETIC COMPLICATIONS, URTICARIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-05-07 | — | — | US | disclosed |
| CN-1305454-A | Anthranilic acid derivatives as inhibitors of CGMP phosphodiesterase | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-07-25 | — | — | CN | disclosed |
| EP-1080069-A1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999054284-A1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-28 | — | — | WO | disclosed |